These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22318789)

  • 21. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.
    Samuels JA; Franco K; Wan F; Sorof JM
    Pediatr Nephrol; 2006 Jan; 21(1):92-5. PubMed ID: 16254730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy.
    Stowe CD; Gardner SF; Gist CC; Schulz EG; Wells TG
    Ann Pharmacother; 2002; 36(7-8):1142-9. PubMed ID: 12086544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADHD, methylphenidate and driving: does some legislation endanger public health?
    Verster JC; Cox DJ
    J Psychopharmacol; 2008 May; 22(3):227-9. PubMed ID: 18541623
    [No Abstract]   [Full Text] [Related]  

  • 25. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
    Lewis H; Lewis J
    Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
    Mick E; McGough JJ; Middleton FA; Neale B; Faraone SV
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):466-72. PubMed ID: 21130132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.
    Mick E; McManus DD; Goldberg RJ
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):534-41. PubMed ID: 22796229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
    Daly MW; Custer G; McLeay PD
    Pharmacotherapy; 2008 Nov; 28(11):1408-12. PubMed ID: 18957001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder.
    Teicher MH; Polcari A; Anderson CM; Andersen SL; Lowen SB; Navalta CP
    J Child Adolesc Psychopharmacol; 2003; 13(1):41-51. PubMed ID: 12804125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methylphenidate induced ST elevation acute myocardial infarction].
    Ruwald MH; Ruwald AC; Tønder N
    Ugeskr Laeger; 2012 Mar; 174(10):647-8. PubMed ID: 22395014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
    Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder.
    Negrao BL; Crafford D; Viljoen M
    Cardiovasc J Afr; 2009; 20(5):296-9. PubMed ID: 19907802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
    Tan M; Appleton R
    Arch Dis Child; 2005 Jan; 90(1):57-9. PubMed ID: 15613514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):35-43. PubMed ID: 16344839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
    Antel J; Albayrak Ö; Heusch G; Banaschewski T; Hebebrand J
    Eur Arch Psychiatry Clin Neurosci; 2015 Apr; 265(3):233-47. PubMed ID: 25149468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.